CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today highlighted its recent clinical and business progress and announced its third quarter 2011 financial results. During the quarter, the company continued to advance its diverse pipeline of novel development candidates designed to target molecular pathways responsible for a broad range of difficult-to-treat diseases.
